For the quarter ended September 2023, Invitae (NVTA) reported revenue of $121.24 million, down 9.2% over the same period last year. EPS came in at -$0.10, compared to -$0.42 in the year-ago quarter.

Invitae, a genetic testing services provider, reported Q1 2023 revenue of $117.4 million, down from Q1 2022's $123.7 million due to exited businesses and geographies. However, after accounting for ...

Invitae is facing two main challenges - assembling a coherent business model from dozens of acquisitions and avoiding a cash crunch looming in 2024/2025. The company has taken decisive action to ...

Invitae (NVTA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one ...

Invitae Corporation NVTA could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ...

SVB Securities analyst Puneet Souda maintained a Hold rating on Invitae (NVTA - Research Report) today and set a price target of $3.00. The companys shares closed yesterday at $2.35. According to ...

Hello, everyone, and welcome to the Invitae first quarter 2023 financial results conference call. My name is Emily, and I will be your conference coordinator today. [Operator instructions] I will now ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people ...